Assessment times for new national applications for the licensing of medicinal products in 2023
The assessment times are divided respectively in human and veterinary medicines. The assessment time of new national applications for the licensing of medicinal products, are calculated in the following way:
- Total assessment time
- Assessment time of the start-up phase.
- Assessment time of remaining phases
Initiated cases with a completed start-up phase
- Assessment times of these cases
For Q4 2023, we make the following observations:
In 2023, we have completed 9 cases, of which 3 cases (33 %) was completed within the performance requirement of 240 days. In 2021 and 2022, 100 % of all cases where finished within the performance requirement. The completed cases in 2023 where received during the Covid-19 pandemic in 2020-2021. Due to the Covid-19 pandemic, the Danish Medicines Agency has not prioritized the assessments times.
While focusing on the total assessment time, we make every effort to meet the maximum time allowed in the start-up phase, and Chart 2 below shows the assessment time for cases with a completed start-up phase (i.e. the assessment time is measured from the close of the start-up phase).
Total assessment times for completed cases
Status for 2023 as at end-December 2023: 9 cases for a human medicine have been completed, 7 cases for human medicines and 2 cases for veterinary medicines.
Total for human and veterinary medicines
- 33 % of the cases finished within the performance requirement's maximum of 240 days (328 days on average).
- 56 % of the cases finished within the performance requirement's maximum of 30 days in the start-up phase (27 days on average).
- 33 % of the cases finished within the performance requirement's maximum of 210 days in the assessment and closing phases (301 days on average).
Total for human medicines
- 29 % of the cases finished within the performance requirement's maximum of 240 days (347 days on average).
- 43 % of the cases finished within the performance requirement's maximum of 30 days in the start-up phase (31 days on average).
- 29 % of the cases finished within the performance requirement's maximum of 210 days in the assessment and closing phases (316 days on average).
Veterinary medicines
- 50 % of the cases finished within the performance requirement's maximum of 240 days (262 days on average).
- 100 % of the cases finished within the performance requirement's maximum of 30 days in the start-up phase (14 days on average).
- 50 % of the cases finished within the performance requirement's maximum of 210 days in the assessment and closing phases (248 days on average).
Chart 1. Assessment times for completed cases
See Table 1-9 for completed cases
The total assessment time is measured against the target time of 240 days for 2023 from the date on which we receive the application until the date of determination (grant or refusal), excluding any clock-stop days.
The assessment time in the start-up phase is measured against the target time of 30 days for 2023 from the date when we receive the application until the procedure start date (day 0).
The assessment time for the remaining phases is measured against the target time of 210 days for 2023 from the procedure start date (day 0) until the date of determination (grant or refusal), excluding any clock-stop days.
Assessment times for initiated cases
Status for 2023 as at end-December 2023:
- Total for human and veterinary medicines: 33 % of the cases finished within the performance requirement's maximum of 30 days (32 days on average).
- Human medicines: 33 % of the cases finished within the performance requirement's maximum of 30 days (32 days on average).
- Veterinary medicines:No cases in 2023
Chart 2. Assessment times for initiated procedures
View Table 10-12 for cases with an initiated procedure
The assessment time is measured against the target time of 30 days for 2023 from the date when we receive the application until the procedure start date (day 0).
For further information, please contact Send an email.